ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.
Company Details
- Employees
- 73
- Founded
- -
- Address
- 323 Allerton Ave, South San Francisco,california 94080,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://alxoncology.com/
- HQ
- South San Francisco, California
Alx Oncology Questions
Alx Oncology's website is http://alxoncology.com/
Alx Oncology's LinkedIn profile is https://www.linkedin.com/company/alx-therapeutics
Alx Oncology has
73 employees.
View email and phone details for 73
employees at Alx Oncology.
Alx Oncology's industry is
Biotechnology Research
Alx Oncology's top competitors are
Atea Pharmaceuticals, Inc,
Atara Biotherapeutics,
Allogene Therapeutics,
Mirum Pharmaceuticals, Inc.,
Revolution Medicines,
Exelixis,
Tallac Therapeutics,
Bridgebio,
Rain Oncology,
Olema Oncology.
Alx Oncology's categories are Biotechnology Research
Alx Oncology's founding year is 2015
